Anal Fissure Treatment Global Market Report 2024

The anal fissure treatment market size has grown strongly in recent years. It will grow from $1.3 billion in 2023 to $1.42 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth observed during the historical period can be attributed to various factors, including limited treatment options available for anal fissures, a rise in awareness regarding these treatments, demographic trends influencing healthcare needs, the development of healthcare infrastructure, and supportive regulatory measures facilitating treatment accessibility and effectiveness. These factors collectively contributed to the growth and development of anal fissure treatments during the historical period.

The anal fissure treatment market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The anticipated growth in the forecast period can be attributed to several factors, including the introduction of innovative treatment approaches for anal fissures, an increase in the incidence rates of such conditions, investments in research and development activities, a shift towards patient-centric care models, and changes in healthcare policies. Key trends expected in the forecast period encompass technological advancements in anal fissure treatments, a growing demand for minimally invasive procedures, a rise in the incidence of anal fissures, a focus on patient-centric approaches to care, and trends related to globalization and market expansion in the healthcare sector.

The burgeoning elderly demographic coupled with unhealthy lifestyle trends is anticipated to act as a driving force for the anal fissure treatment market. As per the World Health Organization (WHO) report in October 2022, it's projected that by 2030, one in six individuals globally will be 60 years or older, rising to a staggering 2.1 billion by 2050. This shift, primarily attributed to age-related factors and detrimental health habits, is foreseen to necessitate increased treatment for anal fissures caused by internal sphincter thinning and tearing.

The escalating incidence of gastrointestinal disorders is poised to significantly contribute to the expansion of the anal fissure treatment market. Gastrointestinal disorders affecting the gastrointestinal (GI) tract are expected to see a concurrent rise in anal fissure occurrences, stimulating demand for specialized treatments. For instance, projections from a May 2021 report by BioMed Central suggest a substantial surge in Inflammatory Bowel Disease (IBD) cases by 2035 across various regions. This surge includes a 2.5-fold rise in Iran, reaching 69 thousand cases, and significant increases in prevalence across North Africa, the Middle East, India, East Asia, high-income Asia-Pacific, and Southeast Asia regions.

The upward trajectory in constipation rates is forecasted to be a driving force behind the growth of the anal fissure treatment market. Constipation, characterized by difficulty passing stools and infrequent bowel movements, often leads to anal fissures due to anus lining damage, necessitating treatment. According to the National Library of Medicine's 2021 data, the global prevalence of constipation was between 12% and 19%, with an estimated annual expenditure of around $7 billion allocated for constipation testing. This escalating prevalence underscores the demand for anal fissure treatments prompted by the increasing constipation rate.

Prominent entities within the anal fissure treatment market are actively innovating by introducing topical treatments specifically tailored to cater to a larger customer base, drive sales, and bolster revenue streams. Anal fissure topical treatments encompass medicinal applications or ointments directly administered to the affected anal fissure area. Notably, in July 2023, Acrux Limited, a pharmaceutical firm based in Australia, announced the initiation of the United States Food and Drug Administration (FDA) review process for Nitroglycerin Ointment, 0.4%. This product's distinctive feature lies in its efficacy in alleviating moderate to severe pain associated with chronic anal fissures, targeting discomfort stemming from the tear in the anus lining. Acrux Limited focuses on advancing advanced-stage projects set for imminent commercialization while simultaneously making significant strides in the development of earlier-stage products, ensuring a diverse and robust product pipeline.

In July 2021, AstraZeneca Plc., a UK-based pharmaceutical and biotechnology enterprise primarily engaged in prescription medicine development and commercialization, successfully completed the acquisition of Alexion Pharmaceuticals Inc. for an undisclosed sum. This strategic acquisition aims to amalgamate resources, leveraging Alexion's expertise, to facilitate AstraZeneca's expansion into rare disease medications and advance their research and development initiatives in pharmaceutical discoveries. Alexion Pharmaceuticals Inc., a US-based biopharmaceutical company renowned for its focus on pioneering life-altering therapies, becomes an integral part of AstraZeneca's journey toward novel medical solutions.

Major companies operating in the anal fissure treatment market report are SRS Life Sciences Inc., Healthy Life Pharma Private Limited, Eisai Co. Ltd., AstraZeneca plc, Bayer AG, Novasep Holding S.A.S., Geri-care Pharmaceuticals Corp., Abbott Laboratories, GlaxoSmithKline plc, Valeant Pharmaceuticals International Inc., Taro Pharmaceutical Industries Ltd., Cook Pharmica LLC, Pfizer Inc., Taj Pharmaceuticals Limited, Troikaa Pharmaceuticals Ltd., Purdue Pharma LP, Allergan Inc., SRS Pharmaceuticals, Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., Enobia Pharma Corporation, Alexion Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals Limited, Sanofi S.A., Eli Lilly and Company, Roche Holding AG, Johnson & Johnson Services Inc., AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc.

North America was the largest region in the anal fissure treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the anal fissure treatment market report during the forecast period. The regions covered in the anal fissure treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anal fissure treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of anal fissure treatments include topical nitroglycerin, calcium channel blockers, stool softeners, and others. Topical nitroglycerin is an ointment specifically employed for the treatment of chronic anal fissures, effectively reducing moderate to severe discomfort. This medication belongs to the nitrate drug family. The major routes of administration for these treatments include topical and oral methods, and they find application in various healthcare settings such as clinics, hospitals, and others.

The anal fissure treatment market research report is one of a series of new reports that provides anal fissure treatment market statistics, including anal fissure treatment industry global market size, regional shares, competitors with a anal fissure treatment market share, detailed anal fissure treatment market segments, market trends and opportunities, and any further data you may need to thrive in the anal fissure treatment industry. This anal fissure treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.